Summary
The motor effects of some DA autoreceptor agonists and apomorphine in rats with bilateral 6-hydroxydopamine lesions of the median forebrain bundle were studied. Whereas (−)-3-PPP, (+)-3-phenethyl-PP and EMD 23448 decreased motility in sham-operated controls, a pronounced hypermotility was induced in 6-OHDA-lesioned rats. 3-PPP enantiomers and apomorphine had similar potency as that found in test models for DA autoreceptor activity in normal rats,e.g. motility inhibition. The DA receptor involvement in the effect of (−)-3-PPP was confirmed by neuroleptic antagonism. (−)-3-PPP and EMD 23448 had similar intrinsic activity as apomorphine, whereas (+)-3-phenethyl-PP and (+)-3-PPP had lower maximal effect. However, the DA autoreceptor agonists differed from apomorphine: The development of postsynaptic supersensitivity to these drugs appeared 4–7 days after the lesion compared to 1–2 days for apomorphine and (+)-3-PPP. Furthermore, no active oral stereotypy was induced by the autoreceptor selective compounds in contrast to the effect observed after apomorphine and (+)-3-PPP. In a separate experiment using circling behaviour in unilaterally 6-OHDA-lesioned rats the different time-course of appearance of supersensitivity to (−)-3-PPP, (+)-3-PPP and apomorphine was confirmed.
After chronic reserpine treatment a similar postsynaptic supersensitivity to (−)-3-PPP was observed with a development time between 4 and 7 days and with a similar intensity as that observed in 6-OHDA-lesioned rats. In contrast, after chronic neuroleptic treatment for 12 days, (−)-3-PPP was unable to induce hyperactivity 3–7 days after withdrawal. The results indicate that DA autoreceptor agonists are able to stimulate postsynaptic DA receptors in conditions without endogenous transmitter supply for at least 4–7 days, but not after chronic receptor blockade in a similar period. This should lead to consideration of DA autoreceptor agonists as potential antiparkin-sonian drugs without stimulant effects on normosensitive postsynaptic DA receptors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arnt, J.: Differential effects of neuroleptics on 3-PPP and amphetamine induced circling behaviour in 6-hydroxy-dopamine lesioned rats. Brit. J. Pharmacol.77, 380 P (1982).
Arnt, J.: Differential behavioural effects of dopamine agonists in developing rats: A study of 3-PPP enantiomers. European J. Pharmacol.91, 273–278 (1983 a).
Arnt, J.: Neuroleptic inhibition of 6, 7-ADTN-induced hyperactivity after injection into the nucleus accumbens. Specificity and comparison with other models. European J. Pharmacol.90, 47–55 (1983 b).
Arnt, J., Christensen, A. V., Hyttel, J., Larsen, J.-J., Svendsen, O.: Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity. European J. Pharmacol.86, 185–198 (1983 a).
Arnt, J., Bøgesø, K. P., Christensen, A. V., Hyttel, J., Larsen, J.-J., Svendsen, O.: Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers, Psychopharmacol.81, 199–207 (1983 b).
Arnt, J., Bøgesø, K. P., Hyttel, J., Larsen, J.-J., Svendsen, O.: Effects of S(+)-3-phenethyl-PP, a putative dopamine autoreceptor agonist with greater autoreceptor selectivity than 3-PPP enantiomers. European J. Pharmacol.102, 91–99 (1984).
Bøgesø, K. P.: Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans. J. Med. Chem.26, 935–947 (1983).
Carlsson, A.: Dopamine receptor agonists: Intrinsic activityvs. state of receptor. J. Neural Transm.57, 309–315 (1983).
Clark, D., Carlsson, A., Hjorth, S., Engel, J., Lindberg, P.: The effect of the enantiomers of 3-PPP on conditioned avoidance responding in the rat. Psychopharmacol.81, 14–17 (1983).
Costall, B., Naylor, R. J., Pycock, C.: Non-specific supersensitivity of striatal dopamine receptors after 6-hydroxydopamine lesion of the nigrostriatal pathway. European J. Pharmacol.35, 275–283 (1976).
Costall, B., Marsden, C. D., Naylor, R. J., Pycock, C. J.: Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei. Brain Research123, 89–111 (1977).
Costall, B., Kelly, M. E., Naylor, R. J.: Does contralateral circling involve action of drugs on hyposensitive striatal dopamine receptors in the hemisphere contralateral to denervation? Neuropharmacol.22, 295–302 (1983).
Creese, I., Iversen, S. D.: The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Research83, 419–436 (1975).
Eriksson, E., Modigh, K., Carlsson, A., Wikström, H.: Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers. European J. Pharmacol.96, 29–36 (1983).
Hjorth, S., Carlsson, A., Wikström, H., Lindberg, P., Sanchez, D., Hacksell, U., Arvidsson, L. E., Svensson, U., Nilsson, J. L. G.: 3-PPP, a new centrally acting DA-receptor agonists with selectivity for autoreceptors. Life Sci.28, 1225–1238 (1981).
Hjorth, S., Carlsson, A., Clark, D., Svensson, K., Wikström, H., Sanchez, D., Lindberg, P., Hacksell, U., Arvidsson, L.-E., Johansson, A., Nilsson, J. L. G.: Cen tral dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology81, 89–99 (1983).
Hyttel, J.: Inhibition of [3H] dopamine accumulation in rat striatal synaptosomes by psychotropic drugs. Biochem. Pharmacol.27, 1063–1068 (1978).
Hyttel, J.: Citalopram-Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog. Neuro-Psychopharmacol. et Biol. Psychiat.6, 277–295 (1982).
Hyttel, J.: SCH 23390-the first selective dopamine D-1 antagonist. European J. Pharmacol.91, 153–154 (1983).
Iorio, L. C., Burnett, A., Leitz, F. H., Houser, V. P., Korduba, C. A.: SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J. Pharmacol. Exp. Ther.226, 462–468 (1983).
König, J. F. R., Klippel, R. A.: The Rat Brain. Baltimore: Williams and Wilkins. 1963.
Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J.: Protein measurement with the folin phenol reagent. J. Biol. Chem.193, 265–275 (1951).
Marsden, C. D.: Basal ganglia disease. Lancet1982, 1141–1146.
Martin, G. E., Haubrich, D. R., Williams, M.: Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99. European J. Pharmacol.76, 15–23 (1981).
Martin, G. E., Jones, J. H., Bendesky, R. J.: Different actions of TL-99 and 3-PPP in producing contraversive turning in the 6-OHDA-lesioned rat. European J. Pharmacol.92, 275–278 (1983 a).
Martin, G. E., Williams, M., Haubrich, D. R.: A pharmacological comparison of 6, 7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl) piperidine (3-PPP) with selected dopamine agonists. J. Pharmacol. Exp. Ther.223, 298–304 (1983 b).
Mikuni, M., Gudelsky, G. A., Simonovic, M., Meltzer, H. Y.: Interaction of (+)-and (−)-3-PPP with the dopamine receptor in the anterior pituitary gland. Life Sci.34, 239–246 (1984).
Muller, P., Seeman, P.: Dopaminergic supersensitivity after neuroleptics: Time-course and specificity. Psychopharmacol.60, 1–11 (1978).
Pastor, G., Fallon, S., Welch, J. J., Liebman, J. M.: Postsynaptic dopamine agonist properties of TL-99 are revealed by yohimbine co-treatment. European J. Pharmacol.87, 459–464 (1983).
Reches, A., Wagner, R. H., Jackson, V., Yablonskaya-Alter, E., Fahn, S.: Dopamine receptors in the denervated striatum: Further supersensitivity by chronic haloperidol treatment. Brain Research275, 183–185 (1983).
Setler, P. E., Malesky, M., McDevitt, J., Turner, K.: Rotation produced by administration of dopamine and related substances directly into the supersensitive caudate nucleus. Life Sci.23, 1277–1284 (1978).
Schultz, W.: Depletion of dopamine in the striatum as an experimental model of parkinsonism: Direct effects and adaptive mechanisms. Progr. Neurobiol.18, 121–166 (1982).
Seyfried, C. A., Fuxe, K., Wolf, H.-P., Agnati, L. F.: Demonstration of a new type of dopamine receptor agonist: an indolyl-3-butylamine. Actions at intact versus supersensitive dopamine receptors in the rat forebrain. Acta Physiol. Scand.116, 465–468 (1982).
Staunton, D. A., Magistretti, P. J., Koob, G. F., Shoemaker, W. J., Bloom, F. E.: Dopaminergic supersensitivity induced by denervation and chronic receptor blockade is additive. Nature299, 72–74 (1982).
Strömbom, U.: Catecholamine receptor agonists. Effects on motor activity and rate of tyrosine hydroxylation in mouse brain. Naunyn-Schmiedeberg's Arch. Pharmacol.292, 167–176 (1976).
Ungerstedt, U.: Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Supplementum367, 95–117 (1971).
Van der Waerden, B. L., Nievergelt, E.: Tables for Comparing Two Samples by X-test and Sign Test. Berlin-Göttingen-Heidelberg: Springer. 1956.
Wikström, H.: Centrally acting dopamine receptor stimulants with special reference to dopamine autoreceptors and stereoselectivity. Thesis Uppsala University (1983).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arnt, J., Hyttel, J. Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats. J. Neural Transmission 60, 205–223 (1984). https://doi.org/10.1007/BF01249094
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01249094